ADAM17 and obesity due to melanocortin 4 receptor deficiency: In diabetes context, it has been demonstrated that the ADAM17 inhibitor JTP-96193 reduced TNF-α release from the fat tissue, prevented development of diabetes, and improved insulin resistance in mouse models of obesity and diabetes respectively.